Reducing risk and improving timelines in the design, development and manufacture of Antibody Drug Conjugates (ADCs) | CPhI North America

 

View, browse and sort the ever-growing list of sessions by pass type, track, and format. With this Session Scheduler, you can build your schedule in advance and access it during the show via export or with the Mobile App, once live. Sessions do fill up and seating is first come, first serve, so arrive early to sessions that you would like to attend.

Reducing risk and improving timelines in the design, development and manufacture of Antibody Drug Conjugates (ADCs)

Juan Cordova (Principle Scientist, Bioconjugation, Abzenal)

Location: bioLIVE Theater

Date: Tuesday, April 30

Time: 1:00pm - 1:20pm

Track: The BPI Theater

Vault Recording: TBD

ADCs are one of the most complicated drug products to develop and manufacture, requiring expertise across multiple fields to collaborate to create the optimal product. This talk will cover how the process can de de-risked, firstly through informed decision based on stability, off-target toxicity, efficacy and manufacturability when choosing a lead candidate and secondly how bringing your ADC component supply chain under one partner organisation reduces timelines, increases speed to market and reduces risk.